Radiosensitization in prostate cancer: mechanisms and targets

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer

(2012) M. Milosevic et al.   CLINICAL CANCER RESEARCH

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks

(2012) Benjamin W. Turney et al.   RADIOTHERAPY AND ONCOLOGY

Inhibition of Neurotensin Receptor 1 Selectively Sensitizes Prostate Cancer to Ionizing Radiation

(2011) N. C. K. Valerie et al.   CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

MLN8054, A Small Molecule Inhibitor of Aurora Kinase A, Sensitizes Androgen-Resistant Prostate Cancer to Radiation

(2011) Luigi Moretti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer

(2011) Jacqueline Vuky et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways

(2011) Ayesha Rashid et al.   Radiation Oncology

A NADPH Oxidase–Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer Cells

(2010) Yulan Sun et al.   CANCER RESEARCH

Altered Expression of Neurotensin Receptors Is Associated with the Differentiation State of Prostate Cancer

(2010) S. L. Swift et al.   CANCER RESEARCH

Downregulation of Human DAB2IP Gene Expression in Prostate Cancer Cells Results in Resistance to Ionizing Radiation

(2010) Zhaolu Kong et al.   CANCER RESEARCH

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

(2010) Michel Bolla et al.   LANCET ONCOLOGY

Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer

(2010) Iftekhar U. Ahmad et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis

(2010) D. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy

(2010) Sajni Josson et al.   PROSTATE

A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer

(2009) Greetta Joensuu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

(2008) Roy Vergis et al.   LANCET ONCOLOGY

The ADAM metalloproteinases

(2008) D EDWARDS et al.   MOLECULAR ASPECTS OF MEDICINE

ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer

(2007) Florian R. Fritzsche et al.   EUROPEAN UROLOGY

Brachytherapy versus radical prostatectomy

(2003) V. Ravery   BJU INTERNATIONAL